Diphenhydramine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Diphenhydramine is a synthetic depressant and deliriant of the ethanolamine antihistamine class. It is the active ingredient in Benadryl, the first antihistamine approved for clinical use. Diphenhydramine is an H1 receptor inverse agonist[1] and muscarinic acetylcholine antagonist,[2] producing its effects by suppressing histamine-driven arousal and blocking cholinergic signaling across the brain.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized by George Rieveschl in 1943, diphenhydramine became the first FDA-approved antihistamine in 1946.[3] Its transition to over-the-counter status in 1985 made it one of the most accessible sedatives worldwide and one of the most commonly misused antihistamines. Rising intentional overdoses have prompted Australia to reclassify it as prescription-only effective July 2026,[4] with several European countries already restricting access.
Subjective effects include sedation, psychomotor impairment, dry mouth, and — at supratherapeutic doses — vivid hallucinations indistinguishable from reality. The deliriant experience is defined by its unsteerable dysphoria — a state of severe cognitive disorganization in which internally generated percepts cannot be distinguished from the external world. Pronounced anxiety, confusion, tachycardia, and memory blackout are characteristic unsought effects.
Diphenhydramine produces physical and psychological dependence with chronic use,[5] and the margin between a therapeutic and a fatal dose is narrow — fatalities are documented at amounts approaching 2 g.[6][7] Tolerance to sedation develops rapidly, driving dose escalation; in overdose, cardiac toxicity from sodium channel blockade compounds the danger,[8] and cumulative anticholinergic exposure is linked to increased dementia risk.[9] Therapeutic pharmacology is well characterized over eight decades, but no controlled study has examined the deliriant experience — the evidence base for supratherapeutic effects rests on poisoning reports and community accounts.
History[edit]
Discovery
Diphenhydramine was synthesized in 1943 by George Rieveschl at the University of Cincinnati, emerging from research into synthetic alternatives to scopolamine rather than a targeted antihistamine program.[3] Parke-Davis licensed the compound, marketed it as Benadryl, and secured FDA approval in 1946 — making diphenhydramine the first antihistamine available for prescription use in the United States.[3][10]
Therapeutic expansion
The compound's utility quickly outgrew allergy treatment. The antiemetic properties of dimenhydrinate — a diphenhydramine salt — were discovered serendipitously when a patient receiving diphenhydramine for hives reported improvement in motion sickness.[10] By 1985, diphenhydramine had transitioned to over-the-counter status in the United States,[11][12] dramatically expanding both accessibility and the potential for intentional misuse.
Regulatory response
Rising rates of serious adverse events — including fatalities linked to social media challenges[13] — have driven regulatory tightening in multiple countries. Australia reclassified diphenhydramine to Schedule 4 (prescription-only) effective July 2026.[4] Germany, the Netherlands, and Sweden already require a prescription.[12] A nine-year forensic review documented 25 diphenhydramine-only fatalities, with 20 of 25 certified as suicides.[7]
The trade name Benadryl — derived from the benzhydryl core of the molecule — became so synonymous with diphenhydramine that many users do not recognize its generic name. In online drug communities, diphenhydramine occupies a singular position as one of the only widely discussed deliriants, and trip reports frequently carry a strongly cautionary tone uncommon for other substance categories. The "Benadryl Challenge" — a social media phenomenon encouraging supratherapeutic doses — drew national attention after multiple pediatric hospitalizations and at least one death.[13]
Chemistry[edit]
Structural class
Diphenhydramine belongs to the ethanolamine subclass of first-generation antihistamines — compounds built on a 2-aminoethanol backbone with two aromatic groups attached via an ether linkage. This architecture produces high lipophilicity, allowing the molecule to cross the blood-brain barrier readily and accounting for the pronounced central nervous system effects that distinguish first-generation antihistamines from their more polar second-generation successors.[14]
Clinically related ethanolamines include doxylamine, carbinoxamine, and clemastine. Dimenhydrinate, the 8-chlorotheophyllinate salt of diphenhydramine, is used primarily as an antiemetic for motion sickness.[10]
Molecular identity
| Molecular formula | C₁₇H₂₁NO |
| Molecular weight | 255.35 g/mol |
| IUPAC name | 2-benzhydryloxy-N,N-dimethylethanamine |
The molecule consists of two unsubstituted phenyl rings joined at a central carbon (the benzhydryl center), linked through an ether oxygen to a two-carbon chain terminating in a dimethylamino group. The diphenylmethoxy moiety occupies the binding pocket of the H1 receptor, as demonstrated by crystal structures of closely related H1R-ligand complexes.[14]
Stereochemistry
Diphenhydramine has one chirality center at the benzhydryl carbon and is sold commercially as a racemate.[15] No stereoselective preparation is standard in clinical use, and whether the individual enantiomers differ meaningfully in pharmacological activity remains an open question.[14]
Salt forms
Three salt forms are used clinically:
- Diphenhydramine hydrochloride — the most common over-the-counter formulation
- Diphenhydramine citrate — used in combination products
- Dimenhydrinate (diphenhydramine 8-chlorotheophyllinate) — used primarily for motion sickness[10]
Pharmacology[edit]
Mechanism of action
Histamine H1 receptor
Diphenhydramine's primary target is the histamine H1 receptor, where it acts as an inverse agonist — reducing the receptor's baseline activity rather than merely blocking histamine from binding.[14][16] It binds the H1 receptor with high affinity,[1][17] producing the antihistaminic, antipruritic, and sedative effects that define its therapeutic profile.
Muscarinic acetylcholine receptors
Diphenhydramine competitively blocks muscarinic acetylcholine receptors across all five subtypes (M1–M5).[2][14][18] This antimuscarinic action produces the familiar anticholinergic side effects — dry mouth, urinary retention, tachycardia, constipation, visual acuity suppression — and, at supratherapeutic doses, drives the delirium and hallucinations that define the compound's deliriant profile.
Ion channel blockade
Diphenhydramine blocks voltage-gated sodium channels with slow dissociation kinetics, functioning as a local anesthetic comparable to lidocaine.[8][16] It also blocks cardiac hERG potassium channels.[6] Together, these two mechanisms create the dual-channel cardiac toxicity that makes overdose dangerous.
NMDA receptors
The compound acts as an open channel blocker at NMDA glutamate receptors,[19] contributing sedative and potentially dissociative properties beyond its histamine and acetylcholine effects.
Secondary targets
Weak serotonin reuptake inhibitor has been documented,[16] though its clinical relevance is uncertain. Diphenhydramine also inhibits histamine N-methyltransferase (HNMT), the enzyme responsible for metabolizing histamine, which may extend the duration of histamine signaling in the brain.[14]
Pharmacokinetics
Diphenhydramine is absorbed rapidly after oral administration, reaching peak blood concentrations within 1.5–2.5 hours.[20][21][16] Oral bioavailability estimates range from 40% to 72% across published studies,[22][16] with the variation likely reflecting differences in formulation and analytical method.
The compound distributes extensively throughout the body, with approximately 98% bound to plasma proteins.[16] Elimination half-life ranges from 4–6 hours in healthy adults[21][22] to 9–15 hours in individuals with liver impairment.[22] The liver handles primary metabolism, and less than 2% of the parent compound appears unchanged in urine.[16]
Diphenhydramine inhibits the liver enzyme CYP2D6, raising blood levels of other drugs processed by this pathway — including beta-blockers such as metoprolol.[18] For prodrugs that depend on CYP2D6 for activation (codeine, tramadol), diphenhydramine may reduce therapeutic efficacy.
Neuroscience[edit]
Where it acts
Diphenhydramine's sedative effects originate from blockade of the tuberomammillary nucleus (TMN), a brain region whose histamine-releasing neurons form a critical component of the arousal system. H1 receptor blockade in the cortex, thalamus, and basal forebrain reduces histaminergic arousal tone, producing sedation and psychomotor slowing.[14]
At supratherapeutic doses, muscarinic acetylcholine receptor blockade disrupts cholinergic circuits in the cortex and hippocampus that are essential for attention, memory, and — critically — distinguishing real perceptions from internally generated ones. This disruption explains the defining feature of anticholinergic delirium: hallucinations that feel indistinguishable from reality.[23][24] NMDA blockade[19] likely adds a dissociative dimension to this experience.
Why it matters
The anticholinergic burden hypothesis proposes that cumulative exposure to drugs like diphenhydramine chronically suppresses cholinergic tone in brain regions critical for memory, potentially accelerating neuronal degeneration. Large population studies consistently link high anticholinergic burden to increased dementia risk,[9] though whether this relationship is causal remains debated.
Controlled studies confirm that even a single therapeutic dose impairs memory — 100 mg of diphenhydramine produces memory deficits comparable to 1.5 mg of lorazepam,[25] despite entirely different primary mechanisms.
No neuroimaging study has examined brain activity during diphenhydramine-induced delirium — the neural signature of deliriant hallucinations is entirely unmapped. Whether the R and S enantiomers differ in brain penetration or subjective effects is unknown.[14] The relative contribution of NMDA blockade[19] versus muscarinic antagonism to the deliriant experience has not been experimentally separated.
Subjective Effects[edit]
The diphenhydramine experience splits cleanly at the boundary between therapeutic and supratherapeutic doses. At therapeutic doses, the pharmacology is straightforwardly sedative — sedation, dry mouth, mild cognitive dulling. Cross that boundary, and the same anticholinergic mechanisms produce a perceptual state unlike any classical psychedelic or dissociative: hallucinations that are not recognized as hallucinations, conversations with people who are not present, and a profound inability to distinguish internal experience from external reality. The experience is not steerable, and set and setting offer far less modulation than for most psychoactive substances — the deliriant state is overwhelmingly dysphoric regardless of context.
Compared to DXM, diphenhydramine produces less dissociation and more anticholinergic toxicity. Compared to scopolamine, it requires substantially higher doses to reach delirium but produces a similar anticholinergic hallucinatory profile once there.
Effect Grid
At common doses (75–150 mg oral), sedation intensifies significantly and is accompanied by pronounced psychomotor impairment — impaired digit symbol substitution, slowed choice reaction time, and degraded sustained attention. Memory impairment becomes notable, with prompted recall at 100 mg comparable to lorazepam 1.5 mg. Anticholinergic effects are more pronounced: persistent dry mouth, blurred vision, urinary retention, and constipation.
Physically, tachycardia becomes more consistent. Mild mydriasis may be detectable. Body heaviness and motor incoordination increase.
This range exceeds recommended OTC dosing. Interaction with alcohol or benzodiazepines at these doses significantly amplifies impairment. Sleep is typically induced within 30–60 minutes, but quality may be poor with fragmented architecture.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Auditory distortion · Auditory misinterpretation · Dreaming suppression · Light sensitivity · Spatial disorientation · Vestibular distortion · Visual drifting · Dreaming enhancement · Auditory enhancement · Depth perception distortion · Auditory suppression · Touch suppression · Music enhancement · Perspective distortion · Proprioceptive distortion · Touch enhancement · Shadow people · External hallucinations · Auditory hallucinations · Visual processing suppression · Object transformations · Object activation · Internal hallucinations · Gustatory hallucination · Olfactory hallucination · Perspective hallucinations
Light sensitivity · Spatial disorientation · Vestibular distortion · Visual drifting · Dreaming enhancement · Auditory enhancement · Depth perception distortion · Auditory suppression · Touch suppression · Music enhancement · Perspective distortion · Proprioceptive distortion · Touch enhancement · Shadow people · External hallucinations · Auditory hallucinations · Visual processing suppression · Object transformations · Object activation · Internal hallucinations · Gustatory hallucination · Olfactory hallucination · Perspective hallucinations
Pupil dilation · Dehydration sensation · Dizziness · Bodily heaviness · Constipation · Sexual arousal suppression · Nausea · Abnormal heartbeat · Headache · Appetite suppression · Involuntary body movements · Spontaneous body sensations · Restlessness · Body high · Muscle relaxation · Muscle tension · Respiratory depression · Body schema distortion · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Wakefulness · Bruxism · Stimulation · Tactile hallucination · Bodily dissociation
Bodily heaviness · Constipation · Sexual arousal suppression · Nausea · Headache · Appetite suppression · Involuntary body movements · Spontaneous body sensations · Restlessness · Body high · Muscle relaxation · Muscle tension · Respiratory depression · Body schema distortion · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Wakefulness · Bruxism · Stimulation · Tactile hallucination · Bodily dissociation
Cognitive fatigue · Thought deceleration · Memory suppression · Cognitive dysphoria · Confusion · Information processing suppression · Pattern recognition suppression · Language suppression · Motivation suppression · Thought disorganization · Creativity suppression · Memory fragmentation · Aesthetic suppression · Suggestibility enhancement · Thought loops · Compulsive redosing urge · Amnesia · Delirium · Delusions
Cognitive dysphoria · Confusion · Information processing suppression · Pattern recognition suppression · Language suppression · Motivation suppression · Thought disorganization · Creativity suppression · Memory fragmentation · Aesthetic suppression · Thought loops · Compulsive redosing urge · Amnesia · Delirium · Delusions
Irritability · Emotional lability · Anhedonia · Empathy suppression · Euphoria
Euphoria
Derealization · Disinhibition · Depersonalization · Emotional susceptibility · Cognitive disconnection · Identity alteration
Cognitive disconnection · Identity alteration
Timeline
First perceptible effects: a gentle wave of drowsiness and faint dry-mouth sensation. At therapeutic doses, onset may be barely noticed; at high doses, early restlessness or unease may emerge.
Sedation deepens progressively. Dry mouth, blurred vision, and motor heaviness become clearly noticeable. At supratherapeutic doses, cognitive clouding and mild confusion begin.
Maximum sedation and anticholinergic effects. At therapeutic doses, deep drowsiness and psychomotor impairment. At deliriant doses, full anticholinergic delirium with formed hallucinations, severe cognitive disorganization, tachycardia, and mydriasis.
Effects remain substantial but begin a slow decline. Sedation persists, anticholinergic symptoms (dry mouth, urinary retention) may remain at peak severity. At deliriant doses, hallucinations may become intermittent but confusion continues.
Gradual return toward baseline. Drowsiness persists but cognitive clarity begins to recover. Anticholinergic symptoms slowly resolve.
Residual grogginess, dry mouth, and mild cognitive dulling may persist for 6–12 hours or into the following day. Sleep architecture may be disrupted despite initial sleep promotion.
⚠ Do not drive or operate machinery until at least 12 hours after dosing, or longer if residual drowsiness persists.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- —
Toxicity
Acute toxicity
The margin between a therapeutic dose and a dangerous one is narrow. Moderate toxicity — hallucinations, agitation, rapid heart rate — appears at approximately 300 mg. Severe toxicity — seizures, cardiac rhythm disturbances, respiratory failure — occurs at doses exceeding 1,000 mg.[6] Fatal doses generally approach or exceed 2 g.
A nine-year forensic review documented 25 diphenhydramine-only deaths, with 20 of 25 certified as suicides — the majority involving individuals with a history of depression.[7] Pediatric surveillance data (2008–2015) identified over 2,000 diphenhydramine-only adverse events, including five deaths.[24]
A 2023 case report documented a 14-year-old's death from a TikTok "Benadryl Challenge" with postmortem blood levels approximately 500 times the therapeutic range.[13]
Heart and circulation
Cardiac toxicity operates through two independent mechanisms. Sodium channel blockade causes QRS widening on ECG, wide-complex rapid heart rate, and potentially fatal rhythm disturbances.[8][26] hERG potassium channel blockade causes QT prolongation and risk of a dangerous rhythm called torsade de pointes.[6]
Sodium bicarbonate is the first-line treatment for QRS widening.[27] Intravenous lipid emulsion may be used for cardiovascular collapse,[28] and extracorporeal membrane oxygenation (ECMO) has been employed for refractory cardiac arrest.[29] Standard dialysis is ineffective because diphenhydramine distributes extensively into body tissues.[6]
Anticholinergic syndrome
The classic presentation — "hot, dry, red, mad" — includes fever, dry skin, flushing, rapid heart rate, dilated pupils, inability to urinate, and delirium. Physostigmine, which boosts acetylcholine levels, reverses the syndrome and is associated with fewer intubations and ICU admissions compared to supportive care alone.[30][31]
Chronic toxicity
Cumulative anticholinergic exposure is associated with increased dementia risk in large population studies.[9] Diphenhydramine contributes a high per-dose anticholinergic burden, making chronic use a particular concern in elderly populations. The American Academy of Sleep Medicine recommends against diphenhydramine for chronic insomnia.[32]
Psychological Risks
At supratherapeutic doses, the primary psychological risk is anticholinergic delirium — a state of severe cognitive disorganization featuring vivid visual, auditory, and tactile hallucinations that are indistinguishable from reality.[23][24] Unlike classical psychedelic experiences, the deliriant state is consistently described as profoundly dysphoric, dominated by fear, confusion, and an inability to recognize the experience as drug-induced.
Hallucinations appear in nearly half of pediatric adverse events,[24] and community reports consistently describe characteristic "shadow people" visions, though no controlled study has formally documented this. Agitation accompanies delirium in approximately one-third of cases.[24]
At therapeutic doses (25–100 mg), psychological effects are limited to sedation, mild memory suppression, and reduced attention.[25] These effects can impair driving and work performance.
Tolerance & Dependence
Tolerance to sedative effects develops rapidly with repeated daily dosing.[32][22] Antihistaminic effects also diminish with continued use. This rapid tolerance is a primary driver of dose escalation in chronic users.
Dependence — both physical and psychological — develops with chronic use.[5] Dose escalation is a documented feature. Cessation after prolonged use produces rebound effect insomnia, anxiety, and irritability.[5]
Drug Interactions
CNS depressants: Diphenhydramine significantly increases the sedation and impairment produced by alcohol and benzodiazepines in controlled studies.[33] Additive or greater CNS and respiratory depression occurs with opioids, sedative-hypnotics, and antipsychotics.[16]
Anticholinergic agents: Combining diphenhydramine with tricyclic antidepressants, antipsychotics, or other first-generation antihistamines produces additive anticholinergic burden, increasing risk of delirium, urinary retention, bowel obstruction, and dangerous overheating.[16]
MAOIs: An interaction concern noted in clinical references due to potential additive CNS and anticholinergic effects. No controlled study data quantify this interaction.safety citation needed
CYP2D6 substrates: Diphenhydramine inhibits CYP2D6, raising blood levels of drugs processed by this enzyme — including beta-blockers (metoprolol, propranolol) and potentially reducing conversion of prodrugs (codeine, tramadol) to their active forms.[18]
Contraindications
Absolute:
- Neonates and premature infants — risk of fatal respiratory depression[16]
- Breastfeeding — excreted in breast milk, may sedate the infant[16]
- Narrow-angle glaucoma — pupil dilation can trigger an acute eye pressure crisis[16]
Relative:
- Enlarged prostate — risk of acute urinary retention[16]
- Liver impairment — half-life extends to 9–15 hours, increasing accumulation risk[22]
- Elderly patients — high anticholinergic burden, falls risk, and cognitive effects; listed in Beers Criteria as potentially inappropriatecitation needed
- Children under 2 years — regulatory agencies recommend against use in this age groupcitation needed
- Restless legs syndrome — antihistamines including diphenhydramine can worsen symptoms[34]
Harm Reduction[edit]
Forms & Identification
Diphenhydramine is widely available in tablets, capsules, liquid gels, and liquid formulations — almost always as the hydrochloride salt. Because it is a mass-produced pharmaceutical, purity concerns differ from those of unregulated substances: the primary risks are not adulteration but dose miscounting (especially with liquid formulations) and combination products that contain additional active ingredients such as acetaminophen, pseudoephedrine, or phenylephrine.
Always verify that any product used contains diphenhydramine as the sole active ingredient. Combination products introduce independent overdose risks — particularly acetaminophen, which causes irreversible liver damage at high doses.
Guidelines
- Verify the product contains diphenhydramine as the sole active ingredient — combination products with acetaminophen, ibuprofen, or decongestants introduce separate, potentially fatal toxicity risks
- Start at the lowest effective dose for any intended purpose; the gap between sedating and deliriant is narrower than most users expect
- Do not combine with alcohol, benzodiazepines, opioids, or other sedating substances — the respiratory and cardiac depression stacks
- Do not combine with other anticholinergic medications (tricyclic antidepressants, antipsychotics, other first-generation antihistamines) — the delirium risk compounds
- If using for sleep, limit to occasional short-term use; tolerance to sedation develops within days, and dose escalation follows
- Hydrate — anticholinergic effects suppress sweating and impair the body's ability to regulate temperature
- Do not drive or operate machinery after taking any dose
Set & Setting
The deliriant experience produced by supratherapeutic diphenhydramine is fundamentally different from psychedelic or dissociative states. Set and setting provide minimal modulation — the anticholinergic delirium is not steerable, and hallucinations are not recognized as such during the experience.
A sober companion is essential at any dose above the therapeutic range, as users routinely lose the ability to distinguish hallucination from reality, may attempt to leave the environment, or may interact with objects and people who are not present. The environment should be physically safe: remove sharp objects, secure exterior doors, and ensure the companion can prevent wandering.
Aftercare & integration. Physical recovery: Rehydrate — anticholinergic effects cause significant fluid loss through dry mucous membranes and impaired sweating. Eat when appetite returns; gastrointestinal slowdown from antimuscarinic effects may persist for 12–24 hours. Expect residual drowsiness, brain fog, and impaired short-term memory for 1–2 days following supratherapeutic doses. Allow extra sleep.
Psychological processing: The hallucinations experienced during anticholinergic delirium can be vivid, frightening, and difficult to distinguish from genuine memories even after the acute experience resolves. If intrusive memories, sleep disturbances, or persistent anxiety develop in the following days, consult a mental health professional. The experience is not psychologically integrable in the way a psychedelic experience might be — there is typically no insight content, only confusion and fear. Accepting this is part of the recovery.
Recovery & Support
Diphenhydramine dependence is documented and underrecognized.[5] Chronic users often escalate from therapeutic sleep-aid doses to hundreds of milligrams daily. Cessation after prolonged use produces rebound effect insomnia, anxiety, and irritability, which drive relapse.
If you are using diphenhydramine daily and have needed to increase your dose to achieve the same effect, consider speaking with a healthcare provider about tapering. Alternative sleep interventions — cognitive behavioral therapy for insomnia (CBT-I), sleep hygiene protocols, and non-anticholinergic medications — are safer long-term options. General substance support resources include SAMHSA's National Helpline (1-800-662-4357, US), and local poison control centers can provide guidance specific to diphenhydramine.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable: dry mouth, drowsiness, mild confusion. Seek immediate help if any of these appear: seizures, chest pain, rapid or irregular heartbeat, difficulty breathing, high fever, inability to urinate, complete disorientation, loss of consciousness, or self-harm behavior.
Immediate steps:
- 1. Call emergency services immediately if the person is having seizures, difficulty breathing, chest pain, or is unresponsive
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Do not induce vomiting
- 4. Do not leave the person alone — they may hallucinate and act on what they perceive
- 5. Remove hazards from the environment: sharp objects, stairs access, exterior doors
What to tell the dispatcher:
State the substance (diphenhydramine/Benadryl), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Medical interventions:
Activated charcoal may be given if within 1 hour of ingestion. Sodium bicarbonate treats cardiac conduction abnormalities. Physostigmine reverses severe anticholinergic delirium when no contraindications exist. Benzodiazepines manage seizures.[6]
Legal Status[edit]
Diphenhydramine is not a controlled substance in any jurisdiction reviewed and is not scheduled under the United States Controlled Substances Act or equivalent international frameworks. Its regulatory status concerns over-the-counter availability rather than controlled substance classification. This status is evolving, with multiple jurisdictions restricting OTC access in response to rising misuse-related adverse events and fatalities.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | OTC (unscheduled) | Prescription from 1946; OTC 1982 (some formulations), 1985 (additional)[11][12] |
| United Kingdom | OTC | Available without prescription[12] |
| Canada | OTC | Available without prescription[12] |
| Australia | Schedule 4 (prescription-only) | Reclassified effective July 1, 2026, driven by rising ED presentations and misuse[4] |
| Germany | Prescription-only | Not available OTC[12] |
| Netherlands | Prescription-only | Not available OTC[12] |
| Sweden | Prescription-only | Not available OTC[12] |
The Australia rescheduling represents a significant precedent for a compound with decades of OTC history. Other jurisdictions with current OTC status may follow as misuse data accumulate.
references
- [1] ^abNakahata N, Ishimoto H, Takahashi A, Ohmori K, Kurita M (1991) Trifluoperazine inhibits phosphoinositide hydrolysis as a histamine H1-receptor antagonist. — European Journal of Pharmacology PMID:1685127
- [2] ^abLiu H, Zheng Q, Farley JM (2006) Antimuscarinic actions of antihistamines on the heart. — Journal of Biomedical Science PMID:16453179
- [3]
- [4]
- [5] ^abcdErbe S, Bschor T (2013) [Diphenhydramine addiction and detoxification. A systematic review and case report]. — Psychiatrische Praxis doi:10.1055/s-0032-1332949
- [6]